The human neuronal glioblastoma cell lines, U251MG (ECACC-09063001), the human breast cancer cell lines MCF-7 (ATCC-HTB-22), the human pancreatic cancer cell lines, PANC-1, the non-small cell lung cancer cell line NCl-H157 (ATCC-CRL-5802) and the human prostate carcinoma cell line PC-3 (ATCC-CRL-1435) were selected to test the cytotoxicity of the peptides. The human microvascular endothelial cell line, HMEC-1 (ATCC-CRL-3243) was utilized to evaluate the cytotoxicity of the peptides on normal human cells. The cell lines were cultured as described previously [12 (link)].
The cell proliferation inhibitory rate was assessed by MTT assay as previously performed [12 (link)] with minor modifications. The peptide was diluted to a final concentration gradient from 1 µM to 100 µM, treating the cell lines for 24 h.
The cell proliferation inhibitory rate was assessed by MTT assay as previously performed [12 (link)] with minor modifications. The peptide was diluted to a final concentration gradient from 1 µM to 100 µM, treating the cell lines for 24 h.
Free full text: Click here
